期刊文献+

盐酸度洛西汀对他林洛尔人体药物动力学的影响 被引量:1

Effect of duloxetine on the pharmacokinetics of talinolol in humans
下载PDF
导出
摘要 目的通过考察盐酸度洛西汀对P糖蛋白底物——他林洛尔药物动力学的影响,探讨盐酸度洛西汀对P-糖蛋白的作用。方法采用随机开放,两周期自身前后对照试验设计,12名健康受试者第1周期单剂量口服他林洛尔1片(50 mg),第2周期受试者服用度洛西汀(30 mg.次-1,2次.d-1),连续服用6 d,于第7日晨加服他林洛尔1片(50 mg)。采用高效液相色谱-串联质谱检测血样药物浓度,计算并比较药物动力学参数。结果受试者多剂量服用盐酸度洛西汀后,他林洛尔的AUC0-60和Cmax由单用时的1 348.54、91.90 ng.mL-1分别增加至1 498.30和125.21 ng.mL-1。AUC和Cmax分别增加了11%和36%。等效性分析显示2周期AUC和Cmax比值的90%置信区间分别为77%~106%和68%~112%,均落于等效范围之外。他林洛尔的其他药动学参数tmax,t1/2,CL/F,V/F在2周期间并无显著性差异。结论盐酸度洛西汀增加了他林洛尔的生物利用度,可能的原因是盐酸度洛西汀抑制了肠道P-糖蛋白的功能,增加了其吸收程度。 Objective To evaluate the effect of duloxetine on P-glycoprotein function by determining the effect of orally administered duloxetine on the pharmacokinetics of talinolol in humans.Methods A self-controlled 2-period experiment was conducted with a randomized,openlabeled design in 12 healthy volunteers.In the 1st period,the volunteers received a single oral dose of 50 mg talinolol.After the 1-week washout,the volunteers received 30 mg duloxetine twice daily for 6 d.On the 7th day,they received 30 mg duloxetine and 50 mg talinolol concomitantly.The concentration of talinolol was determined by HPLC-ESI-MS/MS,and the pharmacokinetic parameters of talinolol were calculated and compared.Results After the subjects were treated with duloxetine,the AUC0-60 and Cmax of talinolol increased from 1 348.54 ng·h·mL-1 to 1 498.30 ng·h·mL-1 and 91.90 ng·mL-1 to 125.21 ng·mL-1,respectively.The AUC0-60 and Cmax of talinolol were increased by 11%and 36%,respectively.The 90% CIs for the ratios of AUC(77%-106%) and Cmax(68%-112%) did not fell in the accepted range(80%-125%).No significant difference in any other pharmacokinetic parameters was observed between the 2 periods(tmax,t1/2,CL/F,and V/F).Conclusion A 6-day treatment with duloxetine increases the oral bioavailability of talinolol.The increase in oral bioavailability of talinolol can be attributed to the inhibition of P-glycoprotein by duloxetine in the small intestine
出处 《中南药学》 CAS 2011年第6期430-433,共4页 Central South Pharmacy
关键词 度洛西汀 P-糖蛋白 他林洛尔 药物动力学 duloxetine P-glycoprotein talinolol pharmacokinetics
  • 相关文献

参考文献11

  • 1Barrand MA, Bagrij T, Neo SY. Multidrug resistance--associated protein: a protein distinct from P-glycoprotein involved in eytoxic drug expulsion [J].Gen Pharma, 1997, 28 (5).. 629-651.
  • 2Scheffer GL, Pijnenborg AC, Smit EF, et al. Multidrug resist- ance related molecules in human and murine lung [J]. J Clin Pathol, 2002, 55 (5):332-339.
  • 3Dietrich CG, Geier A, Oude Elferink RP. AN2 of oral bioavail- ability: transporters as gatekeepers in the gut [J]. Gut, 2003, 52 (12): 1788-1795.
  • 4Chandra P, Brouwer KL. The complexities of hepatic drug transport: current knowledge and emerging concepts [J]. Pharm Res, 2004, 21 (5): 719-735.
  • 5Sun J, He ZG, Cheng G, et al. Multidrug resistance P-glyco- protein: crucial significance in drug disposition and interaction. Med Sci Monit. 2004, 10 (1): RA5-14.
  • 6Maurer H, H. Tenberken O, Kratzsch C, et al. Screening for library-assisted identification and fully validated quantification of 22 beta-blockers in blood plasma by liquid chromatography-mass spectrometry with atmospheric pressure chemical ionization [J].J Chromatog. A, 2004, 1058 (1-2): 169-181.
  • 7Ulrike W, Hildegard SL, Ernst M. Evidence for intestinal se- cretion as an additional clearance pathway of talinolol enati- omers: concentration- and dose-dependent absorption in vitro and in vivo [J].Pharmaceutic Res, 1996, 13 (4): 514-522.
  • 8Dan P, Yaron D, Dina M, et al. Fluoxetine inhibits multidrug resistance extrusion pumps and enhances responses to chemo- therapy in syngeneic and in human xenograft mouse tumor mod- els [J]. Cancer Res, 2004, 64 (20), 7562-7569.
  • 9Johanna W, Dormann SM, Martin-Faeklam M, et al. Inhibition of P-glycoprotein by newer antidepressants [J].J Pharmaacol Exp Ther, 2003, 305 (1), 197-204.
  • 10Thomas grate, reinhard ortel. Intestinal secretion of intrave- nous talinolol is inhibited by luminal R-verapamil [J].Clin Pharmacol Ther, 1999, 66 (3): 239-245.

同被引文献4

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部